TCRX
NASDAQTScan Therapeutics Inc.
News · 26 weeks32+60%
2025-12-142026-06-07
Mix1890d
- Other6(33%)
- SEC Filings6(33%)
- Insider6(33%)
Latest news
25 items- PRCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic MalignanciesCollaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan's lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to commercialization Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan's lead TCR-T therapy candidate for patients with acute myeloid leukemia (AML) and myelodysplastic syndr
- INSIDERSEC Form 4 filed by Director Baker Bros. Advisors Lp4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicholson Garry A4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Woods Keith4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- INSIDERSEC Form 4 filed by Director Gruia Gabriela4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Dorton Katina4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- INSIDERSEC Form 4 filed by Director Klencke Barbara4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TScan Therapeutics Inc.SCHEDULE 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)
- SECSEC Form 10-Q filed by TScan Therapeutics Inc.10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateEarly data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of 2026 Initiation of Phase 1 study of TSC-102-A01 and TSC-102-A03 targeting CD45 in patients with HLA types A*01:01 and A*03:01 planned for the second half of 2026 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients w
- PRTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingWALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29ᵗʰ Annual Meeting being held May 11 – 15 in Boston, MA as well as virtually. Poster Presentation Details: Title: Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation Authors: Hannah L Bader, Kos
- SECSEC Form DEF 14A filed by TScan Therapeutics Inc.DEF 14A - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceWALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TSca
- SECSEC Form PRE 14A filed by TScan Therapeutics Inc.PRE 14A - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECSEC Form 8-K filed by TScan Therapeutics Inc.8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRCombination Therapies Reshape Oncology: A $748B Market Shifts Standard of CareIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 19, 2026 /CNW/ -- USANewsGroup.com News Commentary -- The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by 2035[1], a structural realignment driven by the shift from single-agent treatments toward synergistic combination platforms and next-gen cell therapies. The immuno-oncology segment alone is projected to expand from $65.22 billion in 2025 to $170.19 billion by 2032[2], as a wave of combination therapy approvals converts tumors once resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ
- SECSEC Form S-8 filed by TScan Therapeutics Inc.S-8 - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECSEC Form 10-K filed by TScan Therapeutics Inc.10-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- SECTScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TScan Therapeutics, Inc. (0001783328) (Filer)
- PRTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePresented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (
- PRTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45, for patients with HLA types A*01:01 and A*03:01 Plans to initiate Phase 1 study of both TSC-102 candidates in the second half of 2026 WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced completion of enrollment into Cohort C of the ALLOHA™ study. Patients in Coh
- PRTScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care ConferenceWALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 2026 at 11:50 a.m. Eastern Time. A webcast of the presentation will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of t
- INSIDERSEC Form 4 filed by Chief Financial Officer Amello Jason4 - TScan Therapeutics, Inc. (0001783328) (Issuer)
TCRX FAQ
7 questionsWhat does TScan Therapeutics Inc. do?
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to...Where does TCRX stock trade?
TScan Therapeutics Inc. (TCRX) is listed on NASDAQ.What sector and industry is TCRX in?
TScan Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did TScan Therapeutics Inc. go public?
TScan Therapeutics Inc. (TCRX) completed its IPO in 2021.What are analysts saying about TCRX?
TScan Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight on 2025-11-14. Recent price targets range from $800.00 to $2200.00.What companies are similar to TCRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TCRX side-by-side with any of them on Quantisnow.How can I track TCRX on Quantisnow?
Quantisnow aggregates TScan Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TCRX to receive live email and push alerts on every new disclosure.